A pilot randomized trial on safety and efficacy of a novel topical combined inhibitor of janus kinase 1/3 and spleen tyrosine kinase for GVHD-associated ocular surface disease

Cornea

Volumn 36, Issue 7, 2017, Pages 799-804

  Kheirkhah, Ahmad ^a   Di Zazzo, Antonio ^a   Satitpitakul, Vannarut ^a,b   Fernandez, Merle ^a   Magilavy, Daniel ^c   Dana, Reza ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b CHULALONGKORN UNIVERSITY   (Thailand)

^c RIGEL PHARMACEUTICALS INC   (United States)

Author keywords

Dry eye disease; GVHD; Janus kinase; Ocular surface disease; Spleen tyrosine kinase

Indexed keywords

EYE DROPS; PROTEIN KINASE SYK INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; ENZYME INHIBITOR; JAK1 PROTEIN, HUMAN; JAK3 PROTEIN, HUMAN; JANUS KINASE 1; JANUS KINASE 3; PROTEIN KINASE SYK; SYK PROTEIN, HUMAN;

ADULT; ADVERSE OUTCOME; ARTICLE; CLINICAL ARTICLE; CONJUNCTIVAL HYPEREMIA; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EYE DISEASE; EYE IRRITATION; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; MALE; MIDDLE AGED; OCULAR SURFACE DISEASE; PHASE 2 CLINICAL TRIAL; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THERAPY EFFECT; AGED; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; CONJUNCTIVA; CORNEA DISEASE; DOUBLE BLIND PROCEDURE; DRY EYE; FLUOROPHOTOMETRY; PATHOPHYSIOLOGY; QUESTIONNAIRE;

ADULT; AGED; CONJUNCTIVA; CORNEAL DISEASES; DOUBLE-BLIND METHOD; DRY EYE SYNDROMES; ENZYME INHIBITORS; FEMALE; FLUOROPHOTOMETRY; GRAFT VS HOST DISEASE; HUMANS; JANUS KINASE 1; JANUS KINASE 3; MALE; MIDDLE AGED; OPHTHALMIC SOLUTIONS; PILOT PROJECTS; SURVEYS AND QUESTIONNAIRES; SYK KINASE;

EID: 85020919651     PISSN: 02773740     EISSN: 15364798     Source Type: Journal    
DOI: 10.1097/ICO.0000000000001206     Document Type: Article

References (34)

1. Jagasia MH, Greinix HT, Arora M, et al. National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 diagnosis and staging working group report. Biol Blood Marrow Transpl. 2015;21:389-401.
2. Shikari H, Antin JH, Dana R. Ocular graft-versus-host disease: a review. Surv Ophthalmol. 2013;58:233-251.
3. Hessen M, Akpek EK. Ocular graft-versus-host disease. Curr Opin Allergy Clin Immunol. 2012;12:540-547.
4. Nassiri N, Eslani M, Panahi N, et al. Ocular graft versus host disease following allogeneic stem cell transplantation: a review of current knowledge and recommendations. J Ophthalmic Vis Res. 2013;8: 351-358.
5. Robinson MR, Lee SS, Rubin BI, et al. Topical corticosteroid therapy for cicatricial conjunctivitis associated with chronic graft-versus-host disease. Bone Marrow Transpl. 2004;33:1031-1035.
6. Kiang E, Tesavibul N, Yee R, et al. The use of topical cyclosporin A in ocular graft-versus-host-disease. Bone Marrow Transpl. 1998;22: 147-151.
7. Tam PM, Young AL, Cheng LL, et al. Topical 0.03% tacrolimus ointment in the management of ocular surface inflammation in chronic GVHD. Bone Marrow Transpl. 2010;45:957-958.
8. O'Shea JJ, Pesu M, Borie DC, et al. A new modality for immunosup-pression: targeting the JAK/STAT pathway. Nat Rev Drug Discov. 2004; 3:555-564.
9. Saemann MD, Zeyda M, Stulnig TM, et al. Janus kinase-3 (JAK3) inhibition: a novel immunosuppressive option for allogeneic transplantation. Transpl Int. 2004;17:481-489.
10. Deng GM, Kyttaris VC, Tsokos GC. Targeting syk in autoimmune rheumatic diseases. Front Immunol. 2016;7:78.
11. Lucas MC, Tan SL. Small-molecule inhibitors of spleen tyrosine kinase as therapeutic agents for immune disorders: will promise meet expect-ations? Future Med Chem. 2014;6:1811-1827.
12. Liew SH, Nichols KK, Klamerus KJ, et al. Tofacitinib (CP-690, 550), a Janus kinase inhibitor for dry eye disease: results from a phase 1/2 trial. Ophthalmology. 2012;119:1328-1335.
13. Huang JF, Yafawi R, Zhang M, et al. Immunomodulatory effect of the topical ophthalmic Janus kinase inhibitor tofacitinib (CP-690, 550) in patients with dry eye disease. Ophthalmology. 2012;119:e43-e50.
14. Stevenson W, Sadrai Z, Hua J, et al. Effects of topical Janus kinase inhibition on ocular surface inflammation and immunity. Cornea. 2014; 33:177-183.
15. Ogawa Y, Kim SK, Dana R, et al. International Chronic Ocular Graft-vs-Host-Disease (GVHD) Consensus Group: proposed diagnostic criteria for chronic GVHD (Part I). Sci Rep. 2013;3:3419.
16. Roskoski R Jr. Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases. Pharmacol Res. 2016;111:784-803.
17. Hodge JA, Kawabata TT, Krishnaswami S, et al. The mechanism of action of tofacitinib-an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis. Clin Exp Rheumatol. 2016;34:318-328.
18. Kiefer F, Brumell J, Al-Alawi N, et al. The Syk protein tyrosine kinase is essential for Fcgamma receptor signaling in macrophages and neutro-phils. Mol Cell Biol. 1998;18:4209-4220.
19. Colonna L, Catalano G, Chew C, et al. Therapeutic targeting of Syk in autoimmune diabetes. J Immunol. 2010;185:1532-1543.
20. Sakimoto T, Ishimori A. Anti-inflammatory effect of topical administration of tofacitinib on corneal inflammation. Exp Eye Res. 2016;145:110-117.
21. Hess AD. Modulation of graft-versus-host disease: role of regulatory T lymphocytes. Biol Blood Marrow Transpl. 2006;12(1 suppl 2):13-21.
22. Okiyama N, Furumoto Y, Villarroel VA, et al. Reversal of CD8 T-cell-mediated mucocutaneous graft-versus-host-like disease by the JAK inhibitor tofacitinib. J Invest Dermatol. 2014;134:992-1000.
23. Jaekel N, Behre G, Behning A, et al. Allogeneic hematopoietic cell transplantation for myelofibrosis in patients pretreated with the JAK1 and JAK2 inhibitor ruxolitinib. Bone Marrow Transpl. 2014;49:179-184.
24. Maffini E, Giaccone L, Festuccia M, et al. Ruxolitinib in steroid refractory graft-vs.-host disease: a case report. J Hematol Oncol. 2016;9:67.
25. Leonhardt F, Zirlik K, Buchner M, et al. Spleen tyrosine kinase (Syk) is a potent target for GvHD prevention at different cellular levels. Leukemia. 2012;26:1617-1629.
26. Luo L, Li DQ, Doshi A, et al. Experimental dry eye stimulates production of inflammatory cytokines and MMP-9 and activates MAPK signaling pathways on the ocular surface. Invest Ophthalmol Vis Sci. 2004;45:4293-4301.
27. Riemens A, Stoyanova E, Rothova A, et al. Cytokines in tear fluid of patients with ocular graft-versus-host disease after allogeneic stem cell transplantation. Mol Vis. 2012;18:797-802.
28. Kerrigan AM, Brown GD. Syk-coupled C-type lectins in immunity. Trends Immunol. 2011;32:151-156.
29. Yamasaki S, Ishikawa E, Sakuma M, et al. Mincle is an ITAM-coupled activating receptor that senses damaged cells. Nat Immunol. 2008;9: 1179-1188.
30. Saboo US, Amparo F, Abud TB, et al. Vision-related quality of life in patients with ocular graft-versus-host disease. Ophthalmology. 2015;122: 1669-1674.
31. Methodologies to diagnose and monitor dry eye disease: report of the Diagnostic Methodology Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf. 2007;5:108-152.
32. Alhatem A, Cavalcanti B, Hamrah P. In vivo confocal microscopy in dry eye disease and related conditions. Semin Ophthalmol. 2012;27:138-148.
33. Kheirkhah A, Qazi Y, Arnoldner MA, et al. In vivo confocal microscopy in dry eye disease associated with chronic graft-versus-host disease. Invest Ophthalmol Vis Sci. 2016;57:4686-4691.
34. Shaheen BS, Bakir M, Jain S. Corneal nerves in health and disease. Surv Ophthalmol. 2014;59:263-285.